Etanercept (Benepali®)

Assessment Status Rapid review complete
HTA ID -
Drug Etanercept
Brand Benepali®
Indication A biosimilar of the TNF-α inhibitor Etanercept (Enbrel®) for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.
Assessment Process
Rapid review commissioned 22/03/2016
Rapid review completed 10/05/2016
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended